Startup profile · funding coverage
ROME Therapeutics funding, valuation and investors
Biotech targeting the genomic repeatome for cancer and autoimmune disease.
Keep track of ROME Therapeutics
Save this profile to your VCT watchlist for a quick return.
Funding, valuation & investors
Answer-first snapshotLatest funding
Series B Extension
$72M · September 2023
Latest known valuation
Not publicly disclosed
Total disclosed equity funding
$122M
Excludes debt, grants, acquisitions, secondaries, and IPO proceeds.
Current status
private
series b · Cambridge, MA
Investors in latest funding
Other: Andreessen Horowitz , ARCH Venture Partners
Overview
ROME Therapeutics is a biotechnology company developing therapeutics by harnessing the 'repeatome' — repetitive DNA sequences that make up more than half the human genome but were long dismissed as junk DNA. Founded with backing from ARCH Venture Partners and GV (Google Ventures), ROME maps how repetitive elements activate innate immune pathways in cancer and autoimmune diseases. The company launched in April 2020 with a $50M Series A co-led by GV and ARCH, followed by a $72M Series B extension in September 2023 with a16z, ARCH, and GV participation. Based in Cambridge, Massachusetts, ROME is building a pipeline of novel therapeutics targeting repeatome-driven disease mechanisms that conventional single-gene approaches miss.
Why ROME Therapeutics is interesting
ROME maps repetitive DNA once dismissed as junk to find innate-immune drug targets — ARCH and GV incubated before a16z joined later rounds.
Product & use cases
ROME Therapeutics develops drugs targeting the repeatome — repetitive genomic elements that drive innate immune activation in cancer and autoimmune diseases.
- Novel cancer therapeutics targeting repeatome-driven innate immunity
- Autoimmune disease treatments via repeatome pathway modulation
- Drug discovery in previously unexplored genomic territory
Key facts
- Series A (Apr 2020): $50M co-led by GV and ARCH Venture Partners
- Series B extension (Sep 2023): $72M with a16z, ARCH, GV participation
- Targets the repeatome — repetitive DNA over half the human genome
- Cambridge, MA based; launched April 2020
Funding history (newest first)
Series B Extension
2023-09 $72MInvestors in our directory
Funds linked from ROME Therapeutics's profile — open a fund page for stage focus and related deal articles.
Competitive landscape
Edge: First-mover in repeatome biology with ARCH and GV incubation. Targets genomic dark matter that conventional drug discovery ignores.
Repeatome biology is emerging science with limited clinical validation. ROME's $122M+ in funding from ARCH, GV, and a16z reflects conviction in the thesis but clinical proof remains ahead. If repeatome targets validate, ROME has first-mover advantage; if not, the platform risk is high.
-
Traditional oncology biotechs incumbent
Target known genes and pathways; miss repeatome-driven mechanisms.
-
Innate pharma companies adjacent
Target innate immunity but not specifically via repeatome biology.
-
Academic repeatome research adjacent
Basic science advancing repeatome understanding; ROME translates to therapeutics.
Notable stories
- ROME launched in 2020 to drug the repeatome — repetitive genomic elements once called junk DNA that drive innate immune activation in disease (company press release).
Industries
Related funding articles
Venture Capital Tracker pieces that cover ROME Therapeutics's financing or category context.
FAQs about ROME Therapeutics
Practical answers founders, operators, and investors typically search for.
Last updated:
Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.